Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0003297,
umls-concept:C0006142,
umls-concept:C0011777,
umls-concept:C0018546,
umls-concept:C0061863,
umls-concept:C0183683,
umls-concept:C0229664,
umls-concept:C0332293,
umls-concept:C0344211,
umls-concept:C1171411,
umls-concept:C1317973,
umls-concept:C1328050,
umls-concept:C1516213,
umls-concept:C1521721
|
| pubmed:issue |
3
|
| pubmed:dateCreated |
1998-8-24
|
| pubmed:abstractText |
There has recently been a marked trend to increasing dose intensity in cancer chemotherapy, with or without peripheral blood stem-cell support, which has been associated with a higher frequency of nausea and vomiting. Antiemetic treatment in this setting has not been extensively analysed. From October 1995 to January 1997, prevention of emesis with granisetron 3 mg/12 h i.v., dexamethasone 12 mg/24 h i.v., haloperidol 0.5 mg/12 h p.o., and loracepam I mg/24 h p.o. was instituted in 30 breast cancer patients treated with high-dose chemotherapy (a 4-day intravenous continuous infusion of cyclophosphamide 1500 mg/m2 per day, thio-TEPA 125 mg/m2 per day and carboplatin 200 mg/m2 per day).A total of 30% of the patients (9/30) obtained complete or major protection on the 4 days of chemotherapy treatment (96.7% (29/30) on day 1, 86.7% (26/30) on day 2, 70% (21/30) on day 3, and 50% (15/30) on day 4). On the days following chemotherapy, 46.7% (14/30) presented fewer than two emetic episodes on day 5, 70% (21/30) on day 6, 83.4% (25/30) on day 7 and, 93.3% (28/30) on day 8. This energic antiemetic combination treatment has hardly any effect in the prevention of emesis, providing complete or major protection of 30% for the 4 days of chemotherapy treatment. Further investigation aimed at improving antiemetic treatment results is necessary.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antiemetics,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Granisetron,
http://linkedlifedata.com/resource/pubmed/chemical/Haloperidol,
http://linkedlifedata.com/resource/pubmed/chemical/Lorazepam
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
May
|
| pubmed:issn |
0941-4355
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
6
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
287-90
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:9629884-Adult,
pubmed-meshheading:9629884-Antiemetics,
pubmed-meshheading:9629884-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:9629884-Breast Neoplasms,
pubmed-meshheading:9629884-Dexamethasone,
pubmed-meshheading:9629884-Dose-Response Relationship, Drug,
pubmed-meshheading:9629884-Drug Administration Schedule,
pubmed-meshheading:9629884-Drug Therapy, Combination,
pubmed-meshheading:9629884-Female,
pubmed-meshheading:9629884-Granisetron,
pubmed-meshheading:9629884-Haloperidol,
pubmed-meshheading:9629884-Hematopoietic Stem Cell Transplantation,
pubmed-meshheading:9629884-Humans,
pubmed-meshheading:9629884-Lorazepam,
pubmed-meshheading:9629884-Middle Aged,
pubmed-meshheading:9629884-Nausea,
pubmed-meshheading:9629884-Palliative Care,
pubmed-meshheading:9629884-Treatment Outcome,
pubmed-meshheading:9629884-Vomiting
|
| pubmed:year |
1998
|
| pubmed:articleTitle |
The antiemetic efficacy of granisetron plus dexamethasone, haloperidol and loracepam in breast cancer patients treated with high-dose chemotherapy with peripheral blood stem-cell support.
|
| pubmed:affiliation |
Servicio Oncología Médica, Instituto Valenciano de Oncología, Valencia, Spain.
|
| pubmed:publicationType |
Journal Article,
Comparative Study
|